

This communication should be viewed by:
 Primary Care Providers, Behavioral Health Providers, Clinical staff

Pharmaceutical Policy Updates Effective June 1, 2024

To view all current MVP Health Care® (MVP) Pharmaceutical policies, *Sign In* at mvphealthcare.com/providers and select *Resources*, then *Medical Policies* then *Pharmaceutical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their statuses. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes** – Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective June 1, 2024, and will be available for viewing on or before May 1, 2024. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Baricitinib	New
Cosmetic Drug Agents	Updated
Valchlor	Reviewed/No Changes
Onychomycosis	Updated
Luxturna	Reviewed/No Changes
Luxturna Part B	Reviewed/No Changes
Parsabiv	Updated
Spesolimab	Reviewed/No Changes
Immunoglobulin Therapy	Updated
Immunoglobulin Therapy Part B	Updated
Growth Hormone Therapy	Updated
Xolair Medicare Part B	Updated
Dupixent	Updated
Diclofenac (topical)	Updated
Topical Agents for Pruritus	Updated
Ritlecitinib	New
Policies effective April 1, 2024	
Spesolimab Part B	Reviewed/No Changes
Duchenne Muscular Dystrophy	Updated
Medicare Part B Step Therapy	Updated
Quantity Limits for Prescription Drugs	Updated
Cystic Fibrosis (Select Oral Agents)	Updated
Izervay	New
Izervay Part B	New
Xolair	Updated

To view all communications, visit mvphealthcare.com/FastFax

